Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prevention of Tumour Occurrence by Targeting Emergent Cancer Neoantigens Through Therapeutic Vaccination in Lynch Syndrome Carriers: a Phase III Clinical Trial.

NCT07609901 is registered in ClinicalTrials.gov with Radboud University Medical Center as lead sponsor.

NCT NCT07609901
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07609901 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prevention of Tumour Occurrence by Targeting Emergent Cancer Neoantigens Through Therapeutic Vaccination in Lynch Syndrome Carriers: a Phase III Clinical Trial.
Lead sponsor
Radboud University Medical Center
Phase
Phase 3
Overall status
Not yet recruiting
Start date
October 1, 2026
Completion date
October 1, 2032
Enrollment
372 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lynch syndrome